Press releases

Learn more
16 / 08 / 2017
Exelixis submits U.S. supplemental new drug application for Cabometyx®(Cabozantinib) fo...
27 / 07 / 2017
Ipsen delivers strong sales growth of 18.8% in the first half of 2017 and upgrades its guidance for...
21 / 07 / 2017
Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatme...
10 / 07 / 2017
Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY o...

Share price

Learn more

Ipsen Investor Day

Investor-Day-2017

FACTS AND FIGURES 2016

Cover of registration document 2016

key figures 2016

Diagram Key figures 2016
Diagram Key figures 2016Learn more

Agenda

Ipsen Investor Day

May 11, 2017

London, United Kingdom

...

Contact

Investor Relations

Phone : +44 (0)1 753 627 721

Phone : +33 (0)1 58 33 53 31

Send an email

About Ipsen

Learn more

2017 financial objectives

 

>+18%
Specialty Care sales

 

>+4%
Consumer Healthcare sales

 

> 24%
Core Operating margin

Learn more
Last update 23/02/2017